Celcuity (CELC) Competitors $12.49 -0.43 (-3.33%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$12.30 -0.19 (-1.52%) As of 06/11/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELC vs. ARDT, PGNY, NHC, PACS, GRAL, TDOC, VRDN, AHCO, CDNA, and AVAHShould you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include Ardent Health Partners (ARDT), Progyny (PGNY), National HealthCare (NHC), PACS Group (PACS), Grail (GRAL), Teladoc Health (TDOC), Viridian Therapeutics (VRDN), AdaptHealth (AHCO), CareDx (CDNA), and Aveanna Healthcare (AVAH). These companies are all part of the "healthcare" industry. Celcuity vs. Its Competitors Ardent Health Partners Progyny National HealthCare PACS Group Grail Teladoc Health Viridian Therapeutics AdaptHealth CareDx Aveanna Healthcare Celcuity (NASDAQ:CELC) and Ardent Health Partners (NYSE:ARDT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking, institutional ownership and profitability. Which has better earnings & valuation, CELC or ARDT? Ardent Health Partners has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Ardent Health Partners, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelcuityN/AN/A-$63.78M-$3.03-4.12Ardent Health Partners$6.02B0.32$53.90M$1.638.17 Do analysts recommend CELC or ARDT? Celcuity presently has a consensus price target of $30.80, indicating a potential upside of 146.60%. Ardent Health Partners has a consensus price target of $20.67, indicating a potential upside of 55.17%. Given Celcuity's stronger consensus rating and higher probable upside, research analysts clearly believe Celcuity is more favorable than Ardent Health Partners.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celcuity 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Ardent Health Partners 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is CELC or ARDT more profitable? Ardent Health Partners' return on equity of 0.00% beat Celcuity's return on equity.Company Net Margins Return on Equity Return on Assets CelcuityN/A -62.66% -39.78% Ardent Health Partners N/A N/A N/A Do insiders and institutionals have more ownership in CELC or ARDT? 63.3% of Celcuity shares are held by institutional investors. 15.8% of Celcuity shares are held by company insiders. Comparatively, 1.7% of Ardent Health Partners shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to CELC or ARDT? In the previous week, Celcuity and Celcuity both had 4 articles in the media. Celcuity's average media sentiment score of 1.74 beat Ardent Health Partners' score of 1.23 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ardent Health Partners 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer CELC or ARDT? Celcuity received 317 more outperform votes than Ardent Health Partners when rated by MarketBeat users. However, 89.66% of users gave Ardent Health Partners an outperform vote while only 67.92% of users gave Celcuity an outperform vote. CompanyUnderperformOutperformCelcuityOutperform Votes34367.92% Underperform Votes16232.08% Ardent Health PartnersOutperform Votes2689.66% Underperform Votes310.34% SummaryArdent Health Partners beats Celcuity on 9 of the 15 factors compared between the two stocks. Get Celcuity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELC vs. The Competition Export to ExcelMetricCelcuityMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$472.95M$3.11B$5.57B$8.62BDividend YieldN/A31.25%5.28%4.18%P/E Ratio-4.7913.9627.1720.06Price / SalesN/A179.33409.72157.10Price / CashN/A57.5638.2534.64Price / Book2.284.817.064.70Net Income-$63.78M-$22.21M$3.23B$247.88M7 Day Performance6.03%3.94%2.89%2.66%1 Month Performance16.95%5.62%9.06%6.40%1 Year Performance-16.73%15.89%31.40%14.07% Celcuity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCCelcuity1.9414 of 5 stars$12.49-3.3%$30.80+146.6%-14.8%$472.95MN/A-4.7940Positive NewsARDTArdent Health Partners3.3043 of 5 stars$13.63-8.3%$20.67+51.6%N/A$1.95B$6.02B8.3624,200Positive NewsPGNYProgyny0.8691 of 5 stars$21.97+1.3%$23.45+6.8%-22.8%$1.88B$1.21B37.88310NHCNational HealthCareN/A$104.46-1.5%N/A+1.2%$1.62B$1.37B13.0912,400Positive NewsPACSPACS Group3.4185 of 5 stars$10.41-0.3%$34.29+229.5%-64.1%$1.59B$3.56B0.0032,433GRALGrail0.5168 of 5 stars$40.03+4.4%$31.50-21.3%N/A$1.44B$130.71M-0.661,360High Trading VolumeTDOCTeladoc Health3.228 of 5 stars$7.40+1.8%$9.60+29.7%-29.0%$1.30B$2.55B-1.285,100VRDNViridian Therapeutics1.8125 of 5 stars$14.86+1.2%$36.70+147.0%+19.5%$1.21B$302K-3.4550Positive NewsAHCOAdaptHealth3.0776 of 5 stars$8.82-0.9%$13.40+51.9%-21.6%$1.19B$3.25B-5.3510,900Positive NewsCDNACareDx3.8059 of 5 stars$19.72+1.0%$30.33+53.8%+34.9%$1.10B$346.42M-7.30740Positive NewsAVAHAveanna Healthcare0.9147 of 5 stars$5.47-0.7%$5.13-6.3%+109.2%$1.07B$2.09B-16.0933,000Positive News Related Companies and Tools Related Companies Ardent Health Partners Competitors Progyny Competitors National HealthCare Competitors PACS Group Competitors Grail Competitors Teladoc Health Competitors Viridian Therapeutics Competitors AdaptHealth Competitors CareDx Competitors Aveanna Healthcare Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELC) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.